<DOC>
	<DOCNO>NCT00003165</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different form may kill tumor cell . PURPOSE : Phase II trial study effectiveness doxorubicin treat woman advance metastatic breast cancer .</brief_summary>
	<brief_title>Doxorubicin Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity doxorubicin-HPMA conjugate ( PK1 ) woman advance breast cancer . OUTLINE : This open label , multicenter study . Patients receive doxorubicin-HPMA conjugate ( PK1 ) intravenous infusion every 3 week . Patients may receive total 6 course treatment absence toxicity progressive disease . PROJECTED ACCRUAL : 14-25 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced metastatic carcinoma breast Bidimensionally measurable disease No brain leptomeningeal disease PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Hemoglobin least 10 g/dL Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 11.7 mg/dL AST/ALT great 2 time upper limit normal ( 5 time upper limit normal presence liver metastasis ) Renal : Creatinine great 1.7 mg/dL Cardiovascular : No concurrent treatment congestive cardiac failure Cardiac function within normal limit MUGA ECHO scan , prior anthracycline therapy Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent nonmalignant systemic disease No active uncontrolled infection No prior history malignant disease except : Squamous cell carcinoma skin Curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunological therapy Chemotherapy : At least 1 prior chemotherapy regimen advance disease ( include adjuvant therapy ) , 2 prior regimen At least 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover Cumulative dose prior epirubicin great 450 mg/m2 Cumulative dose prior doxorubicin great 240 mg/m2 No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Low dose steroid therapy allow dose establish least 4 week prior study Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : No concurrent experimental therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>